Hope in sight TM

Our research is bringing hope to people affected by vision loss and blindness

Donate Now


In this video, learn about CERA’s research into gene therapies that could halt or even reverse vision loss in patients with conditions such as inherited retinal diseases and glaucoma.

Science and Research

Learn how CERA’s next generation gene therapy research could transform the treatment of eye diseases including age-related macular degeneration and diabetic eye disease.


The 2023 Annual Review People in focus celebrates everyone who helps CERA deliver innovative vision research that has real-life impact.

Celebrating Cerulea Clinical Trials

Cerulea Clinical Trials, CERA’s new not-for-profit clinical trials centre, is up and running.
Learn how Cerulea will transform the delivery of ophthalmic clinical trials, increase community access to sight-saving therapies and deliver excellence for clinicians, trial participants and sponsors.

Read more

Take part in research

Help shape the future of vision research by taking part in a clinical study.
Find out how you can take part in studies at CERA and Cerulea Clinical Trials for eye conditions including age-related macular degeneration, corneal conditions, diabetic retinopathy, glaucoma and inherited retinal disease.

Learn more

Latest News


13 July 2024

CERA Deputy Director and Head of Ophthalmic Neuroscience Professor Peter van Wijngaarden has been appointed Executive Director of The Florey.


20 May 2024

Cerulea Clinical Trials, launched today in Melbourne, will bring more international trials to Victoria and give people living with vision loss and blindness early access to sight-saving therapies.


06 June 2024

Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years


09 May 2024

Thanks to tireless research, it’s hoped people will be diagnosed with ‘dry’ age-related macular degeneration earlier and have clear pathways to treatments.

Eye-news emails are sent to subscribers once a month

Newsletter Subscribe
Receive Appeals